Stay updated on Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial

Sign up to get notified when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The record now details a Georgetown University biomarker study of nivolumab plus ipilimumab for advanced mucosal or acral lentiginous melanoma, including its eligibility criteria, treatment plan, outcomes, and study documents. It reports that the study was terminated for lack of enrollment, with 14 participants enrolled.
    Difference
    52%
    Check dated 2026-11-07T13:23:28.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The footer’s displayed site revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-10-31T13:58:22.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    A site-wide NIH notice appears above the ClinicalTrials.gov error page, linking to transition updates and describing a shift from “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-24T14:50:01.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T14:38:35.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1. The page continues to display a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-10T15:35:02.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    The study record page now displays an error state instead of the trial details, indicating the page is inaccessible. Navigation elements and the site footer remain visible, showing a generic error presentation.
    Difference
    18%
    Check dated 2026-09-19T18:46:46.000Z thumbnail image

Stay in the know with updates to Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Biomarker Study in Melanoma: Nivolumab + Ipilimumab Clinical Trial page.